Syneos Health-Shortening the distance from lab to life.

Syneos HealthTM. Creating Biopharmaceutical Acceleration.

One year ago, INC Research and inVentiv Health came together to create Syneos Health, the industry’s only true end-to-end solution. Today, we are a seamless global company that combines world-renowned clinical and commercialization capabilities with today’s advanced science, data and business technologies to make possible real advances in biopharmaceutical development.

BAM:

BAM is an end-to-end concept, working across our clinical and commercial capabilities and driven by each and every one of our approximately 24,000 employees. Importantly, it also incorporates many unique Syneos Health disciplines including the Trusted Process®, Syneos One, the Syneos Health Data Lake Ecosystem, Real World Evidence and our deep therapeutic expertise — each providing a constant stream of insights focused on two critical areas: patient behavior and process acceleration.

At Syneos Health, we believe that BAM is the future of biopharmaceutical development. But more importantly to our customers, it is the key to shortening the distance from lab to life®.

Dynamic Assembly™ :

Intentionally Source Agnostic to Remain Nimble and Ahead of the Curve.

Syneos One™ :

Syneos One is the most powerful expression of our Biopharmaceutical Acceleration Model (BAM). A fully integrated, insights-driven product development methodology. This proprietary methodology provides a unique combination of asset strategy and execution to maximize value from early concept through to commercialization.

The Trusted Process® :

The Trusted Process is our proprietary, metrics-driven methodology initially developed to manage all aspects of your clinical studies. This unique, four-step approach delivers faster results while maintaining data integrity and reducing operational risk and variability.

Real World Evidence :

More Than Data: Creating Commercial Value Through Innovative Real World Evidence Practices

RWE generation delivers:

• The supportive data needed for regulators to approve and license.
• The evidence of value needed by payers to authorize and pay for drugs.
• The evidence physicians need to prescribe a drug with confidence.
• And, ultimately, the right information for patients to adhere to a therapy regimen and optimize outcomes.